Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 24, 2025 20:24 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

The phase 3 study of toripalimab's subcutaneous injection (JS001sc) has met primary endpoints